Scottsdale, AZ (PRWEB) January 27, 2010
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA), lupus. vasculitis, polymyositis and scleroderma.
To develop this analysis, entitled “Thought Leader Insight & Analysis: Rheumatology,” MedPredict conducted primary interviews with U.S.and European-based rheumatology thought leaders following the American College of Rheumatology 2009 conference.
“This report highlights key learnings from ACR, focusing on data that suggests any advantage for newer biologicals and small molecules compared to the standards of care for the treatment of rheumatoid arthritis,” according to Jeff Berk, MedPredict’s president. “The Thought Leaders also provide insight into divergent activities and results pertaining to lupus, vasculitis, polymyositis and scleroderma.”
Key mechanisms of action discussed: BLYS, CCR, CD20, CTLA4, GMCSF, JAK, IL-6 / IL-17, Interferon, MEK, PDE4, RANKL. Syk, and TNF.
Companies/Partnerships mentioned: Abbott, Alder/BMS, Amgen/Wyeth/Pfizer, Array, AstraZeneca, Bristol-Myers Squibb, Celgene, Centocor/Schering-Plough (Merck), Genentech/Roche, Genentech/Roche/Chugai, GlaxoSmithKline/Human Genome Sciences, Incyte, LaJolla/Adamis, Lilly, MedImmune, Merck Serono, Millennium/Takeda, Morphosys, Novartis, Rigel, Trubion/Pfizer, and UCB.
This report can be purchased by contacting MedPredict (http://www.medpredict.com) or calling (513) 271-1924.
MedPredict publishes periodic reports to keep clients up-to-date on emerging trends and competitive activity, based on primary interviews with global thought leaders, The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.